Lipe & Dalton
VRTX icon

Lipe & Dalton’s Vertex Pharmaceuticals VRTX Stock Holding History

Lipe & Dalton’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.97M Hold
3,761
– – 0.91% 36
2026
Q2 		$1.87M Sell
3,761
-235
-6% -$104K 0.87% 38
2026
Q1 		$1.78M Hold
3,996
– – 0.93% 35
2025
Q4 		$1.81M Sell
3,996
-250
-6% -$108K 0.9% 36
2025
Q3 		$1.66M Sell
4,246
-60
-1% -$25.1K 0.82% 40
2025
Q2 		$1.92M Sell
4,306
-275
-6% -$127K 1.04% 37
2025
Q1 		$2.22M Sell
4,581
-400
-8% -$186K 1.24% 31
2024
Q4 		$2.01M Sell
4,981
-10
-0.2% -$4.64K 1.06% 33
2024
Q3 		$2.32M Sell
4,991
-50
-1% -$24K 1.17% 33
2024
Q2 		$2.36M Sell
5,041
-94
-2% -$40.8K 1.27% 29
2024
Q1 		$2.15M Hold
5,135
– – 1.11% 34
2023
Q4 		$2.09M Buy
5,135
+100
+2% +$36.9K 1.13% 33
2023
Q3 		$1.75M Hold
5,035
– – 1.05% 32
2023
Q2 		$1.77M Sell
5,035
-50
-1% -$16.8K 1.01% 33
2023
Q1 		$1.6M Sell
5,085
-100
-2% -$30K 0.92% 36
2022
Q4 		$1.5M Sell
5,185
-50
-1% -$15.2K 0.86% 37
2022
Q3 		$1.52M Sell
5,235
-10
-0.2% -$2.88K 0.95% 37
2022
Q2 		$1.48M Buy
5,245
+400
+8% +$107K 0.86% 38
2022
Q1 		$1.26M Buy
4,845
+650
+15% +$154K 0.62% 44
2021
Q4 		$921K Hold
4,195
– – 0.44% 55
2021
Q3 		$761K Sell
4,195
-205
-5% -$40K 0.39% 55
2021
Q2 		$887K Buy
4,400
+245
+6% +$51.2K 0.46% 52
2021
Q1 		$893K Sell
4,155
-225
-5% -$49.4K 0.5% 49
2020
Q4 		$1.04M Buy
+4,380
New +$1M 0.64% 46

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Lipe & Dalton's VRTX Position: Q3 2026 in Review

Lipe & Dalton held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 3,761 shares worth $1.97M. The position accounts for 0.91% of the portfolio, ranked #36.

Lipe & Dalton first reported a position in VRTX in Q4 2020 and has held it in 24 quarters since. The position peaked at $2.36M in Q2 2024. 749 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Lipe & Dalton held 3,761 shares of Vertex Pharmaceuticals worth $1.97M as of Q3 2026.
  • Lipe & Dalton left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up 0.91% of Lipe & Dalton's portfolio in Q3 2026, its #36 holding.
  • Lipe & Dalton first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • Lipe & Dalton's Vertex Pharmaceuticals position peaked at $2.36M in Q2 2024.
  • 749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Lipe & Dalton's 13F filing for Q3 2026, filed 15 Oct 2026.